Oral Cancer Foundation News Team - A

About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2089 blog entries.

E-cigarettes found to cause change in mouth bacteria – which could lead to gum disease or oral cancer

Source: theconversation.com
Author: Beth Daley

E-cigarettes are a popular alternative to smoking, but we still know very little about the effects of them on our health. While numerous studies have explored the effect of e-cigarettes on our lungs, heart, and overall health, one important and often overlooked consideration is what effect they have on our microbiome. But a recent study has found e-cigarettes change the bacteria in our mouths. These bacterial changes can lead to disease, if left unchecked.

Our microbiome is the living community of bacteria, fungi, and viruses that keep us healthy. We often hear a lot about our gut microbiome, but our oral microbiome is probably just as important to our overall health. It’s the second and most diverse microbiota next to the gut, home to over 1,000 species of microbes. It’s the gateway to the rest of our digestive system and plays a key role in helping us break down foods.

Our oral microbiome also wards off potentially harmful microbes by preventing them from reproducing. A healthy oral microbiome reduces the chances of developing infections or disease.

A recent study in Science Advances(1) investigating the effect of e-cigarettes on our oral microbiome found that e-cigarettes have a negative impact on the diversity of the bacteria present. They also cause an immune response from cells, which can lead to long-term damage to the surrounding cells.

Our oral microbes are not only the first to experience e-cigarette vapour, they’re also exposed to higher concentrations of the chemicals. This arguably makes them most likely of any of the body’s microbes to experience the negative effects of e-cigarettes. Changes in the balance of our mouth microbes can lead to some severe diseases, such as tooth decay and gum disease, or leave us susceptible to infections from localised gum disease that can trigger heart disease or respiratory infections or systemic infections like sepsis, which can be fatal. Some of these infections and diseases have also been associated with oral cancers.

For this particular study, 123 participants were recruited and split into five groups: smokers, non-smokers, e-cigarette users, former smokers currently using e-cigarettes, and those that use both. The team collected dental plaque samples to find out more about the microbes present and the genes they have, as well as fluid from the gums to know how the human body has reacted to these microbes. They also grew bacteria in the lab after exposing them to cigarette smoke and e-cigarette vapour.

Bacteria changes
The study found that those who used e-cigarettes had very similar species of microbes, suggesting e-cigarettes played a role in how the microbial community forms and exists. However, there were some significant differences in the smokers group, non-smoker group and e-cigarette groups, all of which had unique oral microbiomes.

When they looked at groups of people that switched from smoking to e-cigarettes and former smokers, they found their microbiota to be very similar – but they were still very different compared to non-smokers. Although this study didn’t specify which bacterial species were affected, even small changes from the healthy bacteria would likely result in negative effects overall. Gram negative bacteria, which are typically considered the “bad microbes”, were common between smokers and e-cigarette users.

This was also the case when the team did lab studies to see what effects e-cigarette vapour and cigarette smoke had on how bacteria grow. They found that the e-cigarette vapour (with or without nicotine) was able to change the way the bacteria grow, by increasing volume and the area covered by the bacteria, which can lead to infections if untreated.

The researchers also found that the microbes in the e-cigarette group had genes that lead to biofilm growth (such as dental plaque). Biofilms make microbes more resilient to the effects of drugs, toxic compounds and the immune system. This suggests that e-cigarettes vapours cause a stress response in the mouth’s microbes.

When stressed, microbes switch on their fight-or-flight genes, making them better able to survive in harsh environments. They do this by producing special enzymes that cause damage to other cells in order for the microbes to use their nutrients and get more space to reproduce. This leads to a cycle of more inflammation, causing a stronger stress response from other cells. However, if we can’t remove these stressed microbes, this sustained, long-term inflammation can lead to severe diseases.

It was also found that when e-cigarette users were compared with non-smokers, e-cigarette users had significantly higher levels of immune cell response chemicals than non-smokers. E-cigarettes users also had lower levels of chemicals that stop this stress response happening. This shows that the body is trying to fight off microbes present, much more so than in non-smokers.

The presence of a diverse microbiota is essential for healthy mouths, healthy bodies, and healthy people. But based on this study’s findings, the use of e-cigarettes has a negative impact on not only the number and types of oral microbes, but on how the microbes behave and how our body responds. Other studies have had similar findings. Though more research into the health effects of e-cigarettes is needed, current evidence suggests ditching them may be best for our overall health.

(1)Sukirth M. Ganesan et al, “Adverse effects of electronic cigarettes on the disease-naive oral microbiome”, Science Advances 27 May 2020: Vol. 6, no. 22,

Scientists to develop pain-free device to detect oral cancer

Source: www.expresshealthcare.in
Author: EH News Bureau staff

£1 million in funding has been awarded to the partnership to develop a functional prototype of a new device that uses Electrical Impedance Spectroscopy (EIS) technology for the early detection of cancerous lesions

In partnership with Zilico, the University of Sheffield is working to develop a pain-free, non-invasive and instantaneous method to detect oral cancer, A research collaboration has been awarded £1million in funding from SBRI Healthcare – an NHS England initiative – to test and develop a pain-free, non-invasive and instantaneous method to detect oral cancer.

Once built and tested, the new device could enable doctors to detect oral cancer earlier and more accurately, reducing the need for patients to have invasive biopsies. This, in turn, could provide better outcomes for patients and significant cost savings for the NHS.

The pioneering device is to be developed with medical device diagnostics company Zilico, born out of a partnership between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust – using the same patented technology as its ZedScan device, which is now in use in the NHS for the early and non-invasive diagnosis of cervical cancer.

Researchers from the University of Sheffield and Sheffield Teaching Hospitals previously demonstrated that the principle of its electrical impedance spectroscopy (EIS) technology, where normal, precancerous and cancerous tissue can be differentiated according to its electrical properties could be useful for detecting oral cancer. The ‘proof of concept’ study involved 47 patients who were recruited from the Charles Clifford Dental Hospital.

Typically, suspicious oral lesions are inspected and diagnosed visually, but the visual indicators of the disease can be misleading or non-apparent in some cases. Many other signs and symptoms of mouth cancer such as constant bad breath and difficulty chewing or swallowing can also be caused by other things than cancer, so a definitive diagnosis can only be made through a biopsy of the tissue.

The new device could enable patients to receive a real-time diagnosis at the primary point of their care and the University is now working with Zilico to develop a functional prototype to be assessed and trialled for use in the NHS.

It is anticipated that the prototype will be ready for testing on a group of volunteers, with the aim to progress the project to a full clinical trial in the next 12 months.

Dr Keith Hunter, Professor of Head and Neck Pathology, at the University of Sheffield’s School of Clinical Dentistry and Insigneo Institute for in silico Medicine, said, “Mouth cancer is on the increase in the UK and globally, and we need new tools to be able to diagnose it earlier, as the survival rate for oral cancer patients depends on how early the disease is diagnosed and treated.

“Electrical impedance spectroscopy could help us to diagnose oral cancer earlier and more accurately, even when these cell changes may not be visually apparent. This could reduce the need for biopsies where there is no disease indicated – helping us to reduce patient anxiety and improve patient comfort.

“Hopefully developing less invasive techniques of diagnosing oral cancer will encourage more people to come forward with oral problems.”

Jamie Healey, Lead Clinical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, said, “We have collaborated with Zilico on the technology developments which form the basis of ZedScan for many years, and we are delighted to see that the clinical applications of electrical impedance spectroscopy are broadening, offering the potential for many more patients to benefit from this novel technology.”

To further the scientific evidence and applications for EIS to be used in diagnosing oral cancer, the collaboration has included a diverse range of University departments, including clinicians and researchers from Insigneo, the School of Health and Related Research (ScHARR) and the Department of Computer Science.

This research included Dr Dawn Walker and Dr James Heath from the Department of Computer Science developing cellular and tissue-scale finite element (FE) models to inform the classification of different tissue types based on EIS measurements collected from normal and diseased oral tissue samples.

Jim Chilcott, Professor of Healthcare Decision Modelling at ScHARR, said, “Using a whole disease modelling approach we are bringing together the available evidence on oral cancer diagnosis, management and treatment to optimise the design of the new oral device and underpin its diagnostic efficacy.”

“An EIS device for the diagnosing of suspected oral cancer has the potential to make an important contribution to the care and management of the disease, quickly removing uncertainty and anxiety for those without cancer and improving the journey to early treatment for those with cancerous and precancerous lesions, Chilcott added.

Aspirin against migraines and cancer

Source: www.swoknews.com
Author: staff

Aspirin never ceases to amaze us. For a medicine that has been around for over 120 years and remains one of the most inexpensive drugs in the pharmacy, we are surprised that there continue to be discoveries.

The latest review of aspirin has to do with its use in the prevention of migraine headaches (American Journal of Medicine, April 2020). One of the authors is Dr. Charles Hennekens. He is considered one of the world’s top scientists by his colleagues. He has contributed to three textbooks and over 750 medical publications.

Dr. Hennekens and his co-authors reviewed the aspirin data over the past several decades. They concluded:

“The totality of evidence, which includes data from randomized trials, suggests that high-dose aspirin, in doses from 900 to 1,300 mg, given at the onset of symptoms, is an effective and safe treatment option for acute migraine headaches. In addition, the totality of evidence, including, some but not all, randomized trials, suggests the possibility that daily aspirin in doses from 81 to 325 mg, may be an effective and safe treatment option for the prevention of recurrent migraine headaches.

“The relatively favorable side effect profile of aspirin and extremely low cost compared with other prescription drug therapies may provide additional clinical options for primary healthcare providers in the treatment of both acute and recurrent migraine headaches.”

Of course, no one should take high doses of aspirin without medical supervision. The same holds true for long-term use. Aspirin can cause stomach irritation and ulcers. And there is always a concern about bleeding.

New migraine medicines such as erenumab (Aimovig), fremanezumab (Ajovy) and galcanezumab (Emgality) could cost between $600 and $700 for a once-monthly injection. Health insurance may not always cover these new treatments. Bayer aspirin costs about 3 cents per pill.

What else can aspirin do? Surprisingly, many obstetricians now recommend aspirin for high-risk pregnancies (U.S. Preventive Services Task Force, Sept. 9, 2014). Low-dose aspirin, prescribed by a physician, may lower the risk of a serious condition called pre-eclampsia (Cochrane Database of Systematic Reviews, Oct. 30, 2019).

Most intriguing of all, aspirin continues to generate excitement with its anti-cancer activity. Scientists at Roswell Park Comprehensive Cancer Center have reported that patients taking low-dose aspirin have better survival statistics against head and neck cancer, as well as non-small-cell lung cancer.

There is also evidence to suggest that regular aspirin use reduces the risk of colorectal and other digestive tract cancers (Annals of Oncology, May 2020). Aspirin may also provide some protection against breast and prostate cancer.

Aspirin must be treated with respect because of the potential for serious adverse reactions. That is why a health professional should always monitor treatment and help weigh benefits and risks with this old OTC medication.

Joe Graedon is a pharmacologist. Teresa Graedon holds a doctorate in medical anthropology and is a nutrition expert. Their syndicated radio show can be heard on public radio. In their column, Joe and Teresa Graedon answer letters from readers. Write to them in care of King Features, 628 Virginia Drive, Orlando, FL 32803, or email them via their website:

FDA approves Gardasil 9, the HPV vaccine, to prevent head-and-neck cancer

Source: www.statnews.com
Author: Matthew Herper

For the past decade, evidence has suggested that Gardasil, the HPV vaccine, could stem an epidemic of throat cancer. But it has also never received approval from the Food and Drug Administration for that use — and it was unclear if it ever would.

Charles Rex Arbogast/AP

On Friday, the agency granted that approval, clearing the latest version of the vaccine, Gardasil 9, to prevent a cancer that affects 13,500 Americans annually. The decision was announced by Gardasil’s maker, Merck.

The decision doesn’t change recommendations about who should get the vaccine, which is already recommended for females and males ages 9 through 45 to prevent cervical, vulvar, vaginal, and anal cancer as well as genital warts. But cancers of the head and neck — mainly those of the tonsils and throat — have been left off the list.

It’s a striking omission, because head and neck cancer, mostly cancer of the throat, is the most common malignancy caused by HPV, the human papilloma virus, in the U.S. According to the Centers for Disease Control and Prevention, there are 35,000 cases of HPV-related cancer in the U.S. annually. On top of the 13,500 cases in the throat, 10,900 are cases of cervical cancer.

“That’s excellent news,” said Stewart Lyman, a pharmaceutical consultant whose doctors discovered a tumor in his throat in 2016. It was removed surgically, and was caused by HPV. “To have this extended to head and neck cancer is really very helpful for helping to inform the public that this serious disease, which has significant morbidity and mortality associated with it, can be prevented with the vaccine,” Lyman said.

Marshall Posner, the director of head and neck medical oncology at the Tisch Cancer Institute, said the approval is “a good thing for the FDA to do” and that he would be “thrilled” if head and neck cancer cases could be reduced through vaccination in coming decades. He said he has “every expectation” that an HPV vaccine would reduce cancer rates.

The original version of the Gardasil vaccine was approved in 2006 for girls and women between the ages of 9 and 26 based on data from clinical trials showing that the vaccine, by preventing HPV infection, could also prevent precancerous cervical lesions. But such lesions don’t exist in head and neck cancer, and it was not clear how to prove the vaccine’s efficacy.

Maura Gillison, now a professor at M.D. Anderson Cancer Center, first connected a subset of head-and-neck cancers to HPV in 1999. But then she and other epidemiologists noticed something: The number of head and neck cancers was rising rapidly, and HPV seemed to be a culprit. What’s more, these sexually transmitted cases seemed different — and somewhat easier to treat. The most common victims were middle-aged men who had contracted the virus decades before.

The FDA is granting what’s known as an accelerated approval, meaning that the decision is contingent on the production of more data and is based on what’s known as a “surrogate endpoint” — an indication that a medicine works that is not foolproof. In this case, the FDA is approving the drug based on data on preventing anogenital infection. In February, Merck began a study of 6,000 men that will test whether patients who receive the vaccine are less likely to get persistent HPV infections in their throats.

Adding another disease to the approval does impact what Merck can say to doctors and patients about HPV and head and neck cancer. “It’s something that was missing in the label,” said Alain Luxembourg, director, clinical research, Merck Research Laboratories. “It is something missing in the conversation between patients and doctors.”

Otis Brawley, an oncology and epidemiology professor at Johns Hopkins University, said that while he is usually opposed to surrogate endpoints, in this case he is comfortable with the decision. “There’s already enough reasons to vaccinate for HPV in men,” he said, adding that doing so broadly might make it possible to eradicate the virus, and the cancers it causes.

For Gillison, who spotted the emergence of HPV throat cancer, it came too late. She pushed Merck to do a study, and said that the one that started in February is coming “10 years plus after when it would have really mattered.” She also thinks that the real reason for the decision is the weight of epidemiologic evidence that she and others produced.

“The fact of the matter is that this approval probably has little whatsoever to do with the anal data per se,” Gillison wrote via text message. “It is because the FDA is made more comfortable with inference because of all the data that has been generated regarding the relationship between oral HPV infection and HPV vaccination outside of vaccine trials in the last 10 years.”

Fighting throat cancer with T cells

Source: www.miragenews.com
Author: press release, Centenary Institute

Research led by the Centenary Institute has discovered that immune cells accumulating within the tumor environment, called tumor-resident T cells, are a critical determinant in survival rates of patients suffering from throat cancer.

Reported in the prestigious ‘Journal for ImmunoTherapy of Cancer’, the research suggests that strategies aiming to boost these T-cells at tumor sites could be beneficial to patients.

“Oropharyngeal squamous cell carcinoma (OPSCC) is a form of throat cancer. It can be caused by environmental factors such as smoking or by human papillomavirus infection (HPV), the same virus that causes cervical cancer in women,” said Ms Rehana Hewavisenti, lead author of the study and researcher at the Centenary Institute and the University of Sydney.

“We knew that patients with HPV-related OPSCC had far better clinical outcomes compared to other OPSCC patients but we didn’t know why,” she said.

In examining over sixty patient samples, Ms Hewavisenti and her colleagues discovered that increased levels of tumor-resident T cells, whether in HPV or non-HPV OPSCC cases, was clearly associated with improved patient survival outcomes.

“It was the accumulation of these immune T-cells, in and around the tumour site that appeared to be key,” said Ms Hewavisenti.

The researchers also found in their study that HPV OPSCC patients generally had far higher levels of tumour-resident T cells compared to their non-HPV OPSCC patient counterparts.

“We think these HPV positive patients tended to have better clinical outcomes as HPV infection is likely to favor the accumulation of these beneficial T-cells within the tumor area,” she said.

Dr Mainthan Palendira, Head of the Centenary Institute’s Human Viral and Cancer Immunology Laboratory and senior author on the research paper believes the research findings have major implications.

“Now that we understand how important this immune response is in relation to OPSCC, we can begin developing new treatment strategies focused on recruiting these favourable tumor-resident T cells directly to tumors,” he said.

Dr Palendira believes that looking at the amount of these T-cells in cancer could help clinicians to personalize the best treatment approach for individual patients.

“We also think that our research demonstrating viral (HPV) links with this tumor-resident T cell accumulation could help in future cancer vaccine development efforts too,” he said.

These 4 diet and lifestyle changes can lower your cancer risk by almost 20%

Source: www.marketwatch.com
Author: Nicole Lyn Pesce

Bad news, booze and beef lovers.

The American Cancer Society has updated its diet and physical activity recommendations to help prevent cancer — and the new guidelines released on Tuesday discourage consuming red meat, processed food, sugar-sweetened drinks — and all alcohol.

The combination of these risk factors (as well as being physically inactive) accounted for at least 18.2% of cancer cases and 15.8% of cancer deaths in the U.S. in 2014, the American Cancer Society reported — making this unhealthy combo the biggest cancer risk factor after cigarette smoking in both men and women.

While the American Cancer Society has advised limiting the consumption of alcoholic drinks to no more to than one per day for women, and two for men since 2012, the new recommendations draw a harder line. “It is best not to drink alcohol,” it says. Period.

For people who still choose to imbibe, the revised guidance reiterates sticking to just one drink a day for women and two for men. And it should be noted that a standard single “drink” is defined as 12 ounces of regular beer, five ounces of wine, and a 1.5-ounce shot of distilled spirits or liquor, which may be smaller than what you actually pour yourself. For example, the University of Cambridge has noted that the average wine glass today holds 15 ounces — or three servings’ worth.

“That recommendation is the synthesis of the evidence and science that finds any amount of alcohol has been shown to increase cancer risk, including breast cancer,” Laura Makaroff, the senior vice president of Prevention & Early Detection at the American Cancer Society, told MarketWatch. “So the recommendation is to limit alcohol. It’s best not to drink, but if you choose to drink, do so in a moderate way.”

The American Cancer Society regularly revises its prevention recommendations, and the new updates are based on reviews of scientific research conducted by health organizations including: the International Agency on Cancer Research; the World Cancer Research Fund/American Institute for Cancer Research; and the U.S. Department of Agriculture and Health and Human Services. They were published in “CA: A Cancer Journal for Clinicians”.

Recent research has warned that many people may need to lay off the sauce. In fact, a recent National Institute on Alcohol Abuse and Alcoholism report found that the number of Americans drinking themselves to death has more than doubled over the last two decades. Alcohol was a factor in nearly 1 million deaths between 1999 and 2017. And multiple studies have suggested a link between alcohol consumption and cancer, including a 2019 report published in the journal BMC Public Health that warned drinking one 750-milliliter bottle of wine a week is associated with the same lifetime cancer risk as smoking five cigarettes a week for men, and 10 cigarettes for women. The National Cancer Institute has also reported “clear patterns” between alcohol consumption and developing head and neck cancer, esophageal cancer, liver cancer, breast cancer and colorectal cancer.

The new American Cancer Society guidelines aren’t just tough on alcohol, however. While they previously encouraged a plant-based diet that limited processed meat, red meat and refined grain products, and recommended maintaining a healthy weight, the new suggestions are much more specific. They include limiting or removing all red and processed meats, sugar-sweetened beverages, high-processed foods and refined grain products from your diet.

“Especially with colorectal cancer, there is an increased risk with people who choose to consume a lot of red meat,” said Makaroff.

Indeed, the World Health Organization’s International Agency for Research on Cancer (IARC) named processed meat a carcinogen in 2015, announcing it had found “sufficient evidence” that its consumption caused colorectal cancer. The IARC has also said that eating red meat is “probably carcinogenic to humans,” based on links to colorectal, pancreatic and prostate cancers.

Such diet and health concerns have helped fuel the growth of plant-based meat alternatives like those from Beyond Meat and Impossible Foods, which have brought their meat-like vegetarian patties to fast-food joints like the Restaurant Brands International chain Burger King. And sugar-sweetened beverages like sodas and sports drinks have been linked to early death, especially in women. Soft drink companies like Pepsi and Coca-Cola have started producing more low-calorie drinks like seltzers and bottled waters to appeal to more health-conscious consumers.

The American Cancer Society recommends piling your plate with a variety of whole, unprocessed foods and vegetables, instead. It highlights dark green, red and orange veggies in particular, as well as fiber-rich legumes like beans and peas. The guide also promotes whole grains, whole fruits in a variety of colors, and overall foods that are “high in nutrients in amounts that help achieve and maintain a healthy body weight.”

“The emphasis here is really about following a healthy eating pattern,” said Makaroff. “When you fill your plate with all of the good things — vegetables, fiber-rich legumes, whole fruits and whole grains — then you’re going to have less room for red and processed meat, which keeps them limited and in moderation.”

Physical activity guidelines have been pumped up, as well. While the American Cancer Society previously recommended engaging in at least 150 minutes of moderate-intensity or 75 minutes of vigorous-activity each week, it now encourages adults to attempt doubling that. “Adults should engage in 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous-intensity physical activity per week,” it reads, adding, “achieving or exceeding the upper limit of 300 minutes is optimal.”

Makaroff noted that reminders to stay active are vital during the coronavirus pandemic. “Many people generally lead a fairly sedentary lifestyle anyway, but then with COVID-19 and shelter-in-place orders, and all of these things we’ve recently gone through and are still going through, keeping an eye on our physical activity is maybe more important than ever, and making sure we are as active as we can be,” she said.

The American Cancer Society recommendations also recognize that access to whole, nutritious foods or safe places to exercise can be challenging for many people. Research suggests that racial inequality runs through education, health care, clean water and sanitation. “Your Zip Code matters a lot more than your genetic code,” said Makaroff. “The environments that we live, learn, work and play in are some of the biggest predictors of our overall health, which includes our risk of cancer.”

So the guidance also calls on public, private and community organizations to implement policy and environmental changes to: increase access to affordable, nutritious foods; provide safe, enjoyable, and accessible opportunities for physical activity; and limit alcohol for all individuals. “Those kinds of community actions are needed to be in place everywhere to help reduce systemic inequities,” said Makaroff.

Read the updated American Cancer Society guidelines in full here. And tips for adopting a healthier diet, squeezing in more exercise and losing weight can also be found in MarketWatch’s no B.S. guide to losing weight.

The American Cancer Society projects that 1.8 million people will be diagnosed with cancer in the U.S. this year. Cancer is the second leading cause of death in the U.S., according to the CDC, killing around 600,000 people a year. The No. 1 killer is heart disease.

And after fighting for their lives, many cancer survivors wind up fighting for their livelihoods. As new chemotherapy treatment and supportive drug-based treatment often tops $10,000 a month, almost one in four of America’s roughly 17 million cancer survivors struggle to pay their medical bills after treatment.

What’s more, an estimated 20% to 30% of survivors do not go back to work three to 18 months after diagnosis, according to the American Journal of Managed Care. And just 57% of low-income women kept their jobs after cancer treatment, compared with 90% of middle-income and 95% of high-income women

Dental record data analytics to improve oral health outcomes

Source: healthitanalytics.com
Author: Jessica Kent

A team from Regenstrief Institute and the Indiana University School of Medicine is applying data analytics techniques to previously inaccessible dental record information with the goal of improving oral health outcomes.

Researchers assessed de-identified data from electronic dental records (EDRs) of 217,887 patients of 99 solo or small dental practices across the US. These EDRs included more than 11 million observations, with observation periods as long as 37 years.

Information on demographics, reason for visit, medical and dental history, social history, tooth characteristics and treatment, and practice and practitioner characteristics was collected for each patient visit.

Dentists could share their data for research in an anonymized process with the help of their EDR vendor. Data from two EDR systems with different formats and operating systems were combined, where interoperability has previously proved difficult with medical data.

Additionally, the study looked at the oral health and treatment options of both insured and uninsured patients, in contrast to previous studies which have relied on insurance records and haven’t provided any information on uninsured patients.

The group found that it was possible to mine and utilize massive amounts of dental record data to determine which dental therapies work and which don’t, which could lead to quality improvement from individual dentists. The study showed that EDR data is reliable for purposes beyond clinical patient care.

Dental practitioners can learn from aggregated data across practices and compare their practice with their peers, researchers said. Information collected at each patient’s visit can contribute to improved outcomes and the development of a true learning health system. This study is the largest to evaluate data quality in a regular patient setting.

“Here in the real world of the dentist’s office we are seeing patients with all kinds of real-world conditions – pain, underlying medical conditions, lack of adequate past oral health care — so this large data set provides a unique insight into the treatments offered in the type of dental offices where most Americans receive care,” said Dr. Thyvalikakath, the founding director of Regenstrief-IU School of Dentistry dental informatics program.

Past research has shown that evaluating dental record data from both insured and underinsured individuals can help inform care delivery and expose gaps in oral care.

A 2019 study showed that racial minorities, lower-income individuals, and uninsured or publicly insured patients were significantly less likely to report that they had received screenings for oral cancer, revealing glaring disparities in oral healthcare.

Investigators can examine this real-world data to better understand the quality of care delivered to patients in different populations.

Now that they have completed the proof-of-concept, the Regenstrief and Indiana School of Medicine team will leverage the data to assess the long-term effectiveness of two common dental procedures performed on permanent teeth: root canal therapy and tooth-colored teeth fillings in rear teeth.

This part of the study will determine how well and how long root canal treated teeth and back teeth filled with tooth-colored fillings continue to function. Data analysis for this portion of the study will help dentists and patients make evidence-based care decisions. Data analysis is currently nearing completion and the researchers will publish their findings in the future.

“Findings derived from patient data in real-world conditions is typically less difficult for clinicians to translate at the point of care than studies performed in large health systems which often represent a patient population that does not mirror the community dentists see in their practices,” said Thyvalikakath.

“We are presenting a mechanism for dentists, many of whom practice by themselves or with only one or two others, to learn from their own experience and from the experiences of their peers to assist in improving skills and facing problems.”

Experts release new guidelines for studies into most effective treatments for HPV-positive throat cancer

Source: en.brinkwire.com
Author: provided by University of Birmingham, United Kingdom

Heightened caution is needed when considering de-escalation trials for patients with Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC), to ensure minimal harm to patients, new guidelines from a group of international head and neck cancer experts have suggested.

HPV-positive oropharyngeal cancer is a cancer of the throat caused by the human papillomavirus—a common, but symptomless group of sexually transmitted viruses. Instances of many throat and neck cancers have declined as smoking rates have fallen, whereas HPV-positive OPC has increased, largely affecting younger patients.

The standard course of treatment for this disease is a combination of cisplatin (a common chemotherapy drug) and radiotherapy. The younger age of the patient population, significantly improved prognosis, and relatively minimal morbidities caused by the standard treatment pathway have led to the popularisation of the concept of treatment de-escalation as a way to improve the quality of life of patients by reducing dosage or frequency of treatment.

These new recommendations, published today in the Journal of Clinical Oncology have been created by the Head and Neck Cancer International Group, a group of experts from nineteen countries, led by the University of Birmingham, UK. The guidelines have been prompted by the recent results of the first three randomised de-escalation trials which suggested a clear detriment in survival when cisplatin is omitted or substituted to minimise side effects.

After a review of available HPV-positive OPC literature, the guidelines recommend an overall need for caution when considering de-escalation options, even in instances where there appears to be possible favourable disease outcomes. Experts also recommend a revised approach to how findings are evaluated during phase II studies to ensure that any potential risks to survival are identified and only if none are present should phase III trials follow.

The guidelines also recommend that de-escalation trials should only be considered for well-defined, very low risk groups and only when there is a strong rationale for investigating a particular treatment strategy. Additionally harm-minimisation techniques should be considered as an alternative. Importantly, treatments should not be implemented into clinical practice before high level evidence is available.

Corresponding author Professor Hisham Mehanna, Director, Institute of Head and Neck Studies and Education (InHANSE) at the University of Birmingham said: “Clinicians and researchers have to be careful when planning and undertaking de-escalation studies, as trials to date have that harm can befall patient. Very controlled and small strides need to be taken when evaluating a possible de-escalation strategy, especially one that removes cisplatin.”

Gambling today: time to ban smoking in casinos

Source: www.si.com
Author: Frankie Taddeo

Casinos are working feverishly towards making guests feel they are not at risk when they travel back to properties with newly implemented safety measures. Among all these new features, there is one important change blatantly missing: prohibiting smoking.

Smoking could easily spread the COVID-19 virus, not only because of the need to remove your mask but because of an individual’s pattern of fingers to mouth while in constant contact with each game they decide to participate in.

Many doctors and experts have gone on record expressing that smoking or exposure to secondhand smoke can lead to coughing which in turn can aid in the spread of the infection. Unfortunately, casino operators don’t appear to have all the health interests of both their guests and employees at the heart of their newly implemented changes. Should that change, now is the time to play the hand being dealt and push all the collective chips into the middle.

Patrons either turning on the news or coming across signs in local establishments are told to avoid touching surfaces others have touched, and then touching your face, mouth, or eyes. In casinos, gamblers continuously touch cards, chips, dice, slot machine buttons, and above all, money. Even those of us who are not medical experts can rationalize that the act of smoking could likely lead to a higher risk of transmission during uncertain times

Also, what about the risks to non-smokers resulting from secondhand smoke? Part of the outline in the current Nevada Gaming Control Board’s reopening plan only requires properties to provide face masks or cloth face coverings upon request. Rather than make it a requirement, they only encourage guests to wear them.

The rationale behind the decision is not about safety, but money. Management running the properties are worried people would stop coming to play, leading to money lost from international tourism where many gamblers do not face such restrictions.

Dating to the days of Frank Sinatra to Sammy Davis Jr, many iconic images depict “Sin City” as a gambling destination where smoking has been synonymous with the lifestyle and imagery of the city’s bustling nightlife. But times have changed, and the goal should be to not only attempt to limit the spread of COVID-19, but to help others avoid the fate of Davis, an avid smoker who eventually passed away from throat cancer.

University of Nevada, Las Vegas gambling expert and author David Schwartz recently told USA Today that the current state of the world presents an ideal time for Nevada gaming operators to consider implementing the change:

“Coming back from COVID-19, both casino patrons and employees may have increased concerns about the presence of cigarette smoke. Given that the customer experience will be very different when casinos reopen, this may be an ideal time for Nevada gaming operators to consider changing where they allow smoking on their properties.”

Additionally, Ashley Herbert, Director of Government Relations with the American Heart Association, recently told the Shreveport Times:

“No one should have to choose between their health and a paycheck…there should not be one class of worker that is unprotected from the harmful effects of secondhand smoke,” Herbert told The Times.

If the focus of state officials is truly on the health and safety of the public, then directives should be made demanding casinos in every state become smoke-free. If considered, the greatest gambling destination in the world can implement a change that validates the health and safety of guests and workers at the forefront of the new reality.

ASCO 2020: New optimized precision radiotherapy can reduce swallowing difficulties for head and neck cancer patients

Source: www.icr.ac.uk
Author: staff

A new optimized intensity-modulated radiation therapy (IMRT) pioneered at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, has been shown to spare head and neck cancer patients’ adverse life-long side effects post treatment.

The initial results from the Dysphagia-Aspiration Related Structures (DARS) trial, funded by Cancer Research UK and the National Institute for Health Research, were presented at the American Society for Clinical Oncology (ASCO) virtual conference this week.

The randomized study found patients with head and neck cancer experienced less adverse side effects with the new precision radiotherapy technique optimized to reduce the risk of swallowing difficulties, known as dysphagia.

Half of newly diagnosed patients with oropharyngeal and hypopharyngeal cancers (tumors of the throat) recruited to the trial received standard IMRT radiotherapy and the other half received IMRT optimized to reduce the radiation dose to the structures related to swallowing and breathing. The trial recruited 112 patients across 23 UK cancer centres.

Difficulties eating and drinking
Patients with head and neck cancer have a 90 percent survival rate but can be left with life changing side effects including swallowing problems, making it difficult to eat and drink. The self-reported measure of swallowing ability as perceived by patients themselves was better in the optimised IMRT group.

Twelve months after treatment, 40 percent of patients given the optimized form of precision radiotherapy reported their swallowing was as good as ever in comparison to just 15 percent on the standard treatment.

The DARS trial was managed by the ICR Clinical Trials and Statistics Unit and supported by strong collaborations between participating hospitals and a multidisciplinary team of doctors, speech and language therapists (SLT), radiographers, research nurses and physicists.

Professor Chris Nutting, Head of the Head and Neck Unit at The Royal Marsden and Joint Head of the Division of Radiotherapy and Imaging at the ICR, said:

“The optimized IMRT treatment will be a game changer for treating head and neck patients in the future. The DARS trial has proved the new technique can spare the swallowing muscles for patients without lessening the success of their treatment.”

Profound impact on quality of life
Dr Justin Roe, Consultant SLT and Joint Head of the Department of Speech, Voice and Swallowing at The Royal Marsden, said:

“Despite improvements in radiotherapy treatments in recent years, people can be left with varying degrees of swallowing difficulty. In some cases, this can have a profound impact on quality of life with people unable to eat and drink safely and comfortably. This has a particular impact during mealtimes and in social situations. It can also have a significant impact on hydration, nutrition and in the most severe cases, can lead to pneumonia. It is very encouraging to see how much improvement there has been in people who received the dysphagia-optimised IMRT.”

Martin Ledwick, Cancer Research UK’s head nurse, said:

“It’s difficult for many of us to imagine not being able to swallow, but this is often the devastating reality for head and neck cancer patients post treatment. The findings of this trial are very exciting and offer hope that this new radiotherapy technique has the potential to make a big improvement to quality of life for these patients after cancer.”